Form 4 for TXG 10x Genomics, Inc.
Accepted 2022-03-24 00:00:00 ET · period of report 2022-03-22 · accession 0001567619-22-007438 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-24 | 2022-03-22 | TXG | Saxonov Serge | CEO, Dir | A - Grant | $0.00 | +58.7K | 971.5K | +6% | $0 |
| D | 2022-03-24 | 2022-03-22 | TXG | Saxonov Serge | CEO, Dir | A - Grant | $0.00 | +146.8K | 146.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-03-22 | A | A | 58,731 | $0.00 | 971,473 | D | — | — | (F1) These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-22 | A | A | 146,827 | $0.00 | 146,827 | D | $69.56 · — to 2032-03-22 | 146,827 Class A Common Stock | (F4) This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |